Use of specific polypeptides of the calgranulin B family for diagnosis and therapy of degenerative, neurological or autoimmune diseases, especially multiple sclerosis

摘要

Use of at least one polypeptide (I), comprising at least part of a protein (II), to prepare a diagnostic, prognostic, prophylactic or therapeutic composition for detection, prevention or treatment of a pathological state associated with degenerative, neurological and/or autoimmune diseases, is new. Use of at least one polypeptide (I), comprising at least part of a protein (II), to prepare a diagnostic, prognostic, prophylactic or therapeutic composition for detection, prevention or treatment of a pathological state associated with degenerative, neurological and/or autoimmune diseases, is new. (II) comprises: (a) any of SEQ IDs 17 (114 aa (amino acids)), 18 (93 aa); 19 (92 aa), 20 (92 aa), 21 (91 aa), 22 (93 aa) or 23 (92 aa), in native form; (b) a sequence at least 70, preferably 98,% identical with (a); or (c) a peptide sequence, or its fragment, belonging to the calgranulin B family. Independent claims are also included for: (1) similar use of nucleic acid fragments (II) that encode (I); (2) similar use of ligands (L) that are specific for (I) or (II); (3) detecting either (I) or (L) by formation of a complex with the other of (I) and (L); (4) detecting (I) by mass spectrometric analysis of a biological fluid; and (5) use of (I) or (II) for testing the efficacy of therapeutic agents. ACTIVITY : Neuroprotective; Nootropic; Antiparkinsonian; Antirheumatic; Antiarthritic; Dermatological; Immunosuppressive; Antiinflammatory. No biological data given. MECHANISM OF ACTION : Modulator of the activity or expression of a calgranulin B family member.